Medical Care
Treatment is indicated if mass effects from the tumor, significant effects from hyperprolactinemia, or both are present.
Although the natural history of prolactinomas is unclear, most microprolactinomas (up to 95%) do not progress to macroadenomas, as determined after a 4- to 6-year observation period. Hence, if a patient with a microprolactinoma has minimal symptoms, the patient can be monitored closely with serial estimations of serum PRL levels combined with imaging studies at yearly intervals. However, if a patient with a microprolactinoma has significant effects from the hyperprolactinemia, treatment is indicated.
Any patient with macroprolactinoma needs treatment because the tumor has already shown a propensity to grow.
Medical treatment
Bromocriptine (BEC) is generally considered to be the agent of choice in the treatment of prolactinoma because of its long track record and safety. As a DA agonist, it decreases the synthesis and secretion of PRL. It also decreases the rate of tumor cell division and growth of individual cells.
Typically, BEC is administered at an initial dose of 1.25 mg nightly with food and gradually increased to 2.5 mg bid in 1-2 weeks, as tolerated. Doses larger than 7.5 mg/d are seldom needed except in the treatment of macroadenomas.
Common adverse effects include nausea, nasal stuffiness, and dizziness associated with orthostatic hypotension. Others include vasospasm in the peripheral circulation and exacerbation or unmasking of depression and psychosis.
In patients intolerant to even small doses of BEC, one alternative is to administer the same daily dose intravaginally once a day, which has almost equal efficacy.
Normalization of PRL levels occurs in 85-90% of all patients with prolactinomas.
In microprolactinomas, PRL levels return to normal within days to a few weeks of starting treatment in almost all patients who can tolerate appropriate doses of BEC. If PRL levels normalize, gonadal function also typically has a near-total recovery. Menses return to normal within a few months. Sometimes, pregnancy can occur before resumption of menstruation; therefore, the couple must be advised to use barrier methods of contraception until normal menses have returned.
In macroprolactinomas, BEC treatment results in some reduction of tumor size in up to 80-85% of the patients. Significant VF improvements have been noted as early as 1-3 days, and significant changes on imaging findings occur as soon as 2 weeks after starting treatment.
In contrast to patients with microadenomas, resolution of hyperprolactinemia is often incomplete in patients with macroadenomas. However, the extent of reduction in tumor size is not well correlated with the changes in serum PRL levels. Nevertheless, reductions in PRL levels always precede tumor shrinkage, and those who do not show a drop in PRL do not have any tumor shrinkage.
A reduction in tumor size is often accompanied by improvement in pituitary function. Examples include improvement in serum testosterone levels and an increase in sperm counts.
Once normalization of PRL levels is achieved and sustained, the dose of BEC is gradually tapered to approximately 2.5 mg/d. If PRL levels and tumor size are stable on the above dose, consider tapering BEC to the lowest dose possible. The patient should be evaluated periodically with monitoring of symptoms, PRL levels, and radiological changes.
Other medical treatments available for patients who do not respond to BEC or those who cannot tolerate BEC
Cabergoline, a long-acting nonergot DA agonist, was recently made available in the United States and is usually better tolerated than BEC. Efficacy profiles are somewhat superior to those of BEC. It offers the convenience of twice-a-week administration, with a usual starting dose of 0.25 mg biweekly to a maximum dose of 1 mg biweekly. Some studies have shown efficacy even with once-a-week dosing. Cabergoline appears to be more effective in lowering prolactin levels and restoring ovulation. Up to 70% of patients who do not respond to BEC respond to cabergoline. The only problem is cost. Side effects are somewhat fewer than with BEC and include headache, nausea, postural hypotension, and fatigue.
Quinagolide, a nonergot DA agonist with a long duration of action, is not yet available for use in the United States. It can be administered once daily. Efficacy and tolerance are comparable to that of BEC.
Pergolide, a drug approved for the treatment of Parkinson disease, is a DA agonist with a long duration of action. Daily doses of 50-150 mcg are nearly as effective as treatment with BEC. Tolerance is comparable to that with BEC. Some patients who do not respond to BEC tend to respond to pergolide and vice versa. Rare cases of valvular heart disease have been reported in users of pergolide much like the lesions noted with use of fenfluramine or in patients with carcinoid tumors. The use of pergolide is therefore not generally recommended in patients with prolactinoma for this reason.
Withdrawal of medical therapy: In some patients with prolactinoma who have adequately responded to medical treatment, withdrawing medical treatment after about 24 months of treatment may be possible. Even though no clear predictive criteria for such successful withdrawal exist, it appears that recurrence of hyperprolactinemia was generally lower in patients with microadenomas than in those with macroadenomas. Hyperprolactinemia recurred more likely in those with tumor remnant on pituitary MRI compared with those without a remnant. In very large adenomas, regrowth of tumor is often seen after withdrawal of medical treatment. In any case, if medical treatment is withdrawn, close clinical, biochemical, and radiologic monitoring is warranted to look for evidence of tumor recurrence.
Radiation treatment
Radiation treatment (XRT) has a limited role in the treatment of prolactinomas. Following conventional XRT, PRL levels normalize in only approximately 25% of patients. The major complication of this treatment is hypopituitarism, which occurs in up to 12.5-80% of patients. The other complications include optic nerve damage and neurologic dysfunction (see Complications).
Because of the excellent results with medical treatment, with or without surgery, XRT is seldom used. XRT is considered only in select cases, ie, with rapid tumor regrowth despite medical and surgical treatment.
Pregnancy and prolactinoma
During pregnancy, a physiologic doubling in the volume of normal pituitary gland occurs. Moreover, prolactin levels increase by 10-fold during this period.
When a woman with prolactinoma presents with infertility and is proceeding with medical treatment for hyperprolactinemia, mechanical (barrier) methods of contraception is advised, until menstrual cycles resume for the first few cycles, so that accurate dating of pregnancy can be performed. BEC is the preferred medical treatment in this situation because of its long safety record. BEC can be discontinued after the first skipped period. This is to prevent unwanted fetal exposure to BEC despite its safety record. However, to date, increased rates of spontaneous abortion, ectopic pregnancy, or teratogenic effects have not been reported with BEC therapy.
Most women with microprolactinomas do not show significant increases in tumor size during pregnancy. Rates of tumor progression of 1-5% have been reported in such women. In contrast, those women with macroadenomas show significant tumor enlargement, up to 15-35%, during gestation secondary to the hormonal stimulation of lactotrophs.
The treatment of pregnant women with prolactinomas must be tailored to the individual patient. In those with microadenomas and in the subgroup of women with intrasellar macroadenomas without significant suprasellar or parasellar extension, BEC can usually be safely discontinued upon conception, and the patient can be monitored clinically for symptoms of tumor enlargement. Periodic monitoring of PRL levels and VFs is not usually required in such women.
In those women with larger macroadenomas, a definitive individualized plan is made only after thorough discussions with the patient. Options include (1) discontinuation of BEC at conception and careful monitoring of PRL levels and VFs, with or without MRI scan evidence of tumor enlargement; (2) prepregnancy transsphenoidal surgery with debulking of the tumor, ie, with the resultant risk of complications (see Complications); and (3) continuation of BEC throughout gestation, with the theoretical risk to the fetus.
Surgical Care
Transsphenoidal pituitary adenomectomy is the preferred surgical treatment in patients with microprolactinoma and most patients with macroprolactinoma. A transcranial approach is used only in patients with large extrapituitary extension. A transcranial pituitary tumor resection is more hazardous, ie, associated with higher mortality and morbidity rates.
A combination of surgery followed by postoperative medical treatment with BEC or one of the other agents is used in patients with incomplete resolution of elevated PRL levels or in those with residual tumors seen on follow-up imaging studies.
In surgical series of patients with microadenomas, normalization of PRL levels is reported in approximately 70-75% of patients. Recurrence rates of approximately 17% are reported. This surgery is associated with low mortality and morbidity rates (approximately 0.3% and 0.4%, respectively).
Recent data from a tertiary center indicate an initial cure rate of approximately 90% and a recurrence rate of 16% for microprolactinomas. However, results vary with the experience of the neurosurgeon and the duration of follow-up. Complications include hypopituitarism, bleeding, cerebrospinal fluid rhinorrhea, and diabetes insipidus (see Complications).
In patients with macroprolactinomas, normalization of the PRL level occurs initially in approximately 30% of patients and the recurrence rate is approximately 15-20%. Mortality and morbidity rates are less than 1% and 6%, respectively.
Indications for surgery
Women who have a microadenoma, desire pregnancy, and cannot tolerate BEC should undergo surgical treatment.
Patients who do not wish to take BEC or one of the other drugs long-term should be considered for surgical treatment.
Patients who do not respond to medical treatment or those who show progression after an initial response to medical treatment should receive surgical treatment.
Consultations
Neurosurgeon